| Sector |
Healthcare
|
Compare with Sector peers |
| Industry |
Pharmaceuticals & Drugs
|
Compare with Industry peers |
| Website | http://www.medicoremediesindia.com / www.medicoremediesindia.net / www.tabletandcapsules.com | |
| Market Cap | 719.89 Cr. | |
| Enterprise Value(EV) | 724.20 Cr. | 2023-09 |
| Financial Indicators | ||
|---|---|---|
| Earnings per share (EPS) | 0.94 | Trailing Twelve Months Ending 2023-09 |
| Price-Earning Ratio (PE) | 92.73 | Trailing Twelve Months Ending 2023-09 |
| Industry PE | 38.52 | Trailing Twelve Months Ending 2023-09 |
| Book Value / Share | 5.74 | Trailing Twelve Months Ending 2023-09 |
| Price to Book Value | 15.12 | Calculated using Price: 86.75 |
| Dividend Yield | 0.00 | Period Ending 2023-03 |
| No. of Shares Subscribed | 8.30 Cr. | 82,984,000 Shares |
| FaceValue | 2 | |
| About Medico Remedies Ltd. | ||
| The company is engaged in manufacturing and selling of pharmaceutical formulation products in India. The company offers formulation pharmacy products including anti-infective, beta lactum, cephalosporin, antimalarial, antiretroviral, and anti-ulcer drugs, as well as antacids; vitamins, haematinics and other supplements and nonsteroidal anti-inflammatory drugs, antihistaminics, anti-diabetics, cardio vascular drugs, diuretics, anti-epileptics, combination drug kits, syrups and creams and gels. | ||
| 1 Day |
|
+8.40% |
| 1 Week |
|
+11.43% |
| 1 Month |
|
+15.94% |
| 3 Month |
|
+18.95% |
| 6 Month |
|
+4.15% |
| 1 Year |
|
+39.76% |
| 2 Year |
|
+205.67% |
| 5 Year |
|
+1785.87% |
| 10 Year |
|
| 9 years | 2015-03 | 2016-03 | 2017-03 | 2018-03 | 2019-03 | 2020-03 | 2021-03 | 2022-03 | 2023-03 | |
| Return on Equity (%) | 7.14 | 7.97 | 10.47 | 5.67 | 5.72 | 5.61 | 8.31 | 13.94 | 18.01 | |
| Return on Capital Employed (%) | 10.01 | 10.86 | 9.39 | 9.05 | 7.79 | 7.66 | 10.13 | 15.09 | 21.88 | |
| Return on Assets (%) | 2.36 | 2.78 | 3.47 | 2.26 | 2.31 | 2.15 | 3.43 | 6.24 | 8.63 |
| Particulars | 10 years | 2015-03 Rs. Cr. | 2016-03 Rs. Cr. | 2017-03 Rs. Cr. | 2018-03 Rs. Cr. | 2019-03 Rs. Cr. | 2020-03 Rs. Cr. | 2021-03 Rs. Cr. | 2022-03 Rs. Cr. | 2023-03 Rs. Cr. | 2023-09* Rs. Cr. |
| Shh. Funds | 14 | 15 | 16 | 27 | 28 | 30 | 32 | 37 | 44 | 48 | |
| Non Curr. Liab. | 1 | 4 | 11 | 3 | 3 | 5 | 5 | 3 | 2 | 2 | |
| Curr. Liab. | 22 | 26 | 21 | 30 | 45 | 40 | 38 | 40 | 43 | 53 | |
| Minority Int. | |||||||||||
| Equity & Liab. | 36 | 46 | 48 | 59 | 76 | 75 | 76 | 79 | 89 | 102 | |
| Non Curr. Assets | 10 | 9 | 10 | 14 | 17 | 19 | 17 | 20 | 23 | 22 | |
| Curr. Assets | 26 | 37 | 38 | 46 | 59 | 57 | 58 | 59 | 66 | 81 | |
| Misc. Exp. not W/O | |||||||||||
| Total Assets | 36 | 46 | 48 | 59 | 76 | 75 | 76 | 79 | 89 | 102 |
| Particulars | 10 years | 2015-03 Rs. Cr. | 2016-03 Rs. Cr. | 2017-03 Rs. Cr. | 2018-03 Rs. Cr. | 2019-03 Rs. Cr. | 2020-03 Rs. Cr. | 2021-03 Rs. Cr. | 2022-03 Rs. Cr. | 2023-03 Rs. Cr. | 2023-09 Rs. Cr. TTM |
| Net Sales | 51 | 67 | 54 | 61 | 98 | 89 | 122 | 121 | 140 | 141 | |
| Other Income | 0 | 0 | 0 | 1 | 2 | 2 | 1 | 2 | 4 | 2 | |
| Total Income | 51 | 67 | 55 | 62 | 100 | 91 | 123 | 123 | 145 | 143 | |
| Total Expenditure | -48 | -63 | -50 | -58 | -95 | -86 | -117 | -114 | -131 | -129 | |
| PBIDT | 3 | 4 | 4 | 4 | 5 | 5 | 6 | 9 | 14 | 14 | |
| Interest | -1 | -1 | -1 | -2 | -1 | -1 | -1 | -1 | -1 | -1 | |
| Depreciation | -1 | -1 | -1 | -1 | -2 | -2 | -2 | -2 | -3 | -3 | |
| Taxation | 0 | -1 | 0 | -1 | -1 | -1 | -1 | -2 | -3 | -3 | |
| Exceptional Items | 0 | ||||||||||
| PAT | 1 | 1 | 2 | 1 | 2 | 2 | 3 | 5 | 7 | 8 | |
| Adjusted EPS | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 1 | 1 | 2 |
| Particulars | 10 years | 2014-03 Rs. Cr. | 2015-03 Rs. Cr. | 2016-03 Rs. Cr. | 2017-03 Rs. Cr. | 2018-03 Rs. Cr. | 2019-03 Rs. Cr. | 2020-03 Rs. Cr. | 2021-03 Rs. Cr. | 2022-03 Rs. Cr. | 2023-03 Rs. Cr. |
| Cash Fr. Operatn. | 3 | 0 | -4 | -3 | 5 | 5 | 1 | -11 | 6 | 8 | |
| Cash Fr. Inv. | -4 | -2 | 0 | -3 | -5 | -4 | -3 | -17 | -2 | -7 | |
| Cash Fr. Finan. | 2 | 3 | 2 | 6 | -1 | -1 | 3 | 18 | -6 | -2 | |
| Net Change | 1 | 0 | -1 | 0 | -1 | 0 | 0 | -10 | -2 | 0 | |
| Cash & Cash Eqvt | 1 | 2 | 1 | 0 | 0 | 0 | 1 | -10 | 1 | 1 |
|
Sat, 11 Nov 2023
Announcement under Regulation 30 (LODR)-Newspaper Publication In Compliance with Regulation 47 of SEBI (LODR) Regulations 2015 please find attached newspaper advertisements for publication of announcement of unaudited financial results for the quarter and half year ended 30th September 2023. |
|
Thu, 09 Nov 2023
Board Meeting Outcome for Outcome Of Board Meeting Held Today Pursuant to Regulation 30 of SEBI (Listing Obligations and Disclosure Requirements) Regulations 2015 we hereby inform you that the Board of Directors at their Meeting held today i.e. 9" November 2023 has inter alia considered and approved the Unaudited Financial Results for the quarter andhalf year ended 30" September 2023 alongwith Auditors Limited Review Report thereon.We wish to inform you that the Board Meeting commenced today at 3.00 P.M and concluded at 5.10P.M |
|
Thu, 09 Nov 2023
Outcome Of Board Meeting Held Today Please find attached Unaudited Financial Results for the quarter and half year ended 30th September 2023 approved at Board meeting held today. |
| Fri, 08 Dec 2023 |
Higher Delivery Quantity
|
Higher Trade Quantity
|
Higher Trade and Delivery Quantity
|
Close Crossing Last Month High
|
Closing Above Previous High
|
Equities
M.F.
Sectors
StockEdge Social